CL2004000409A1 - Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu - Google Patents

Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu

Info

Publication number: CL2004000409A1
Authority: CL; Chile
Prior art keywords: replaced; cilo; chinazoline; dependents; oxi
Prior art date: 2003-03-03

Application number

CL200400409A

Other languages

English (en)

Inventor

E Gonzales Iii Dean Mitc Jesus

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-03

Filing date

2004-03-02

Publication date

2005-01-07

2004-03-02 Application filed by Vertex Pharma filed Critical Vertex Pharma

2005-01-07 Publication of CL2004000409A1 publication Critical patent/CL2004000409A1/es

Links

150000001875 compounds Chemical class 0.000 title 2
-1 AMINO Chemical class 0.000 title 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title 1
208000002193 Pain Diseases 0.000 title 1
208000005298 acute pain Diseases 0.000 title 1
239000011575 calcium Substances 0.000 title 1
229910052791 calcium Inorganic materials 0.000 title 1
230000001684 chronic effect Effects 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
239000011734 sodium Substances 0.000 title 1
229910052708 sodium Inorganic materials 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Immunology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

CL200400409A 2003-03-03 2004-03-02 Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu CL2004000409A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US45145803P	2003-03-03	2003-03-03
US46379703P	2003-04-18	2003-04-18

Publications (1)

Publication Number	Publication Date
CL2004000409A1 true CL2004000409A1 (es)	2005-01-07

Family

ID=32965550

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200400409A CL2004000409A1 (es)	2003-03-03	2004-03-02	Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu

Country Status (20)

Country	Link
US (2)	US7678802B2 (es)
EP (1)	EP1608632B1 (es)
JP (1)	JP5247027B2 (es)
KR (1)	KR20050108379A (es)
AR (1)	AR044502A1 (es)
AT (1)	ATE453629T1 (es)
AU (1)	AU2004217891B2 (es)
BR (1)	BRPI0408026A (es)
CA (1)	CA2517844A1 (es)
CL (1)	CL2004000409A1 (es)
DE (1)	DE602004024873D1 (es)
ES (1)	ES2338553T3 (es)
IL (1)	IL170636A (es)
NO (1)	NO20054546L (es)
NZ (1)	NZ542664A (es)
PE (1)	PE20041059A1 (es)
RU (1)	RU2378260C2 (es)
TW (1)	TW200426147A (es)
UY (1)	UY28215A1 (es)
WO (1)	WO2004078733A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7713983B2 (en) *	2003-03-03	2010-05-11	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
JP4895806B2 (ja) *	2003-04-09	2012-03-14	エクセリクシス，インク．	Ｔｉｅ−２モジュレータと使用方法
US7410975B2 (en) *	2003-06-20	2008-08-12	Coley Pharmaceutical Group, Inc.	Small molecule toll-like receptor (TLR) antagonists
AR045037A1 (es) *	2003-07-10	2005-10-12	Aventis Pharma Sa	Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
CA2545340A1 (en) *	2003-11-10	2005-05-26	Synta Pharmaceuticals, Corp.	Fused heterocyclic compounds
KR20070057914A (ko) *	2004-09-02	2007-06-07	버텍스 파마슈티칼스 인코포레이티드	이온 채널 조절인자로서 유용한 퀴나졸린
US7718658B2 (en) *	2004-09-02	2010-05-18	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
US7928107B2 (en) *	2004-09-02	2011-04-19	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
US8283354B2 (en)	2004-09-02	2012-10-09	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
RU2007127315A (ru) *	2004-12-17	2009-01-27	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Способы получения 4-аминохиназолинов
NZ556248A (en)	2005-03-14	2010-06-25	Neurosearch As	Pyrazolyl-quinazoline potassium channel modulating agents and their medical use
EP1891039A1 (en) *	2005-05-20	2008-02-27	Vertex Pharmaceuticals Incorporated	Quinoline derivatives useful as modulators of ion channels
FR2891829A1 (fr) *	2005-10-12	2007-04-13	Sanofi Aventis Sa	Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique
GB0522715D0 (en)	2005-11-08	2005-12-14	Helperby Therapeutics Ltd	New use
KR20080073749A (ko)	2005-11-14	2008-08-11	버텍스 파마슈티칼스 인코포레이티드	전압 개폐 이온 채널 조절제로서 유용한 퀴나졸린
KR20080070749A (ko) *	2005-11-23	2008-07-30	페인셉터 파마 코포레이션	개폐 이온 통로를 조절하기 위한 조성물 및 방법
JP2009520700A (ja) *	2005-12-21	2009-05-28	ペインセプターファーマコーポレーション	依存性イオンチャネルを調節するための組成物および方法
CA2652307A1 (en) *	2006-04-10	2007-10-18	Painceptor Pharma Corporation	Compositions and methods for modulating gated ion channels
CA2649995A1 (en)	2006-04-26	2007-11-08	Cancer Research Technology Limited	Amino-ethyl-amino-aryl (aeaa) compounds and their use
EP2043654A2 (en)	2006-06-12	2009-04-08	Vertex Pharmaceuticals, Inc.	Thienopyrimidines useful as modulators of ion channels
EP2589597B1 (en) *	2006-08-22	2019-03-06	Technion Research & Development Foundation	Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (PBR)
JP2010505794A (ja)	2006-10-03	2010-02-25	ノイロサーチアクティーゼルスカブ	カリウムチャネル調節剤として有用なインダゾリル誘導体
CA2663436A1 (en)	2006-10-04	2008-04-10	Pfizer Products Inc.	Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008069976A2 (en)	2006-12-01	2008-06-12	President And Fellows Of Harvard College	Compounds and methods for enzyme-mediated tumor imaging and therapy
KR20090129488A (ko) *	2007-03-22	2009-12-16	버텍스 파마슈티칼스 인코포레이티드	야누스 키나아제의 억제제로서 유용한 ｎ-헤테로사이클릭 화합물
US8759348B2 (en) *	2007-05-17	2014-06-24	Helperby Therapeutics Limited	Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
WO2008157500A1 (en) *	2007-06-17	2008-12-24	Kalypsys, Inc.	Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US20090023773A1 (en) *	2007-06-27	2009-01-22	Painceptor Pharma Corporation	Compositions and methods for modulating gated ion channels
WO2009053694A1 (en) *	2007-10-24	2009-04-30	Cancer Research Technology Limited	Therapeutic oxy-phenyl-aryl compounds and their use
BRPI0922010A2 (pt) *	2008-11-14	2015-12-15	Hoffmann La Roche	dervivados de quinazolina como antagonistas receptores de nk3
WO2010135568A1 (en) *	2009-05-22	2010-11-25	Exelixis, Inc.	Benzoxazepines as inhibitors of mtor and their use to treat cancer
WO2010135524A1 (en) *	2009-05-22	2010-11-25	Exelixis, Inc.	Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
WO2010151597A1 (en) *	2009-06-26	2010-12-29	Schering Corporation	Methods for using pyrrolo-benzo-1,4-diazines as sodium channel blockers
US20110053916A1 (en) *	2009-08-14	2011-03-03	Vertex Pharmaceuticals Incorporated	Pyrimidine compounds as tuberculosis inhibitors
EP2473487B1 (en)	2009-09-03	2016-10-26	Bristol-Myers Squibb Company	Quinazolines as potassium ion channel inhibitors
AR079814A1 (es)	2009-12-31	2012-02-22	Otsuka Pharma Co Ltd	Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
TW201139406A (en) *	2010-01-14	2011-11-16	Glaxo Group Ltd	Voltage-gated sodium channel blockers
WO2012027495A1 (en)	2010-08-27	2012-03-01	University Of The Pacific	Piperazinylpyrimidine analogues as protein kinase inhibitors
KR20130095772A (ko)	2010-10-05	2013-08-28	퍼듀 퍼머 엘피	나트륨 채널 차단제로서 퀴나졸린 화합물
EP2651405A2 (en)	2010-12-14	2013-10-23	Electrophoretics Limited	Casein kinase 1 (ck1 ) inhibitors
WO2013070852A2 (en) *	2011-11-08	2013-05-16	Emory University	Compounds and compositions used to epigenetically transform cells and methods related thereto
WO2013143319A1 (zh) *	2012-03-26	2013-10-03	中国科学院福建物质结构研究所	喹唑啉衍生物及其用途
EP2865671B1 (en) *	2012-06-22	2017-11-01	Sumitomo Chemical Company, Ltd	Fused heterocyclic compound
US20150259649A1 (en)	2012-11-08	2015-09-17	Emory University	Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
US9765039B2 (en)	2012-11-21	2017-09-19	Zenith Epigenetics Ltd.	Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en)	2012-11-21	2015-07-07	Zenith Epigenetics Corp.	Cyclic amines as bromodomain inhibitors
JP2016507496A (ja)	2012-12-21	2016-03-10	ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈＥｐｉｇｅｎｅｔｉｃｓＣｏｒｐ．	ブロモドメイン阻害剤としての新規複素環式化合物
US9688688B2 (en)	2013-02-20	2017-06-27	Kala Pharmaceuticals, Inc.	Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP2016516691A (ja) *	2013-03-11	2016-06-09	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	カリウムイオンチャネル阻害剤としてのイソキノリン
US9242966B2 (en) *	2013-03-11	2016-01-26	Bristol-Myers Squibb Company	Phthalazines as potassium ion channel inhibitors
KR102307566B1 (ko)	2013-06-21	2021-10-05	제니쓰 에피제네틱스 리미티드	신규한 바이사이클릭 브로모도메인 억제제
CN105473581B (zh) *	2013-06-21	2019-04-23	齐尼思表观遗传学有限公司	作为溴结构域抑制剂的新取代的双环化合物
CA2919948C (en)	2013-07-31	2020-07-21	Zenith Epigenetics Corp.	Novel quinazolinones as bromodomain inhibitors
AU2014341966B2 (en) *	2013-11-01	2017-08-17	KALA BIO, Inc.	Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en)	2013-11-01	2018-02-13	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
CN103755649A (zh) *	2013-12-31	2014-04-30	李增	一种喹唑啉衍生物及其作为血管生成抑制剂的应用
AU2015223049B2 (en) *	2014-02-27	2019-03-21	Merck Patent Gmbh	Heterocyclic compounds as NaV channel inhibitors and uses thereof
CN106458933B (zh)	2014-04-23	2021-03-05	泰克年研究发展基金会公司	基于喹唑啉支架的化合物、其药物组合物及使用方法
JP6899323B2 (ja) *	2014-10-14	2021-07-07	ラホーヤインスティテュートオブアレルギーアンドイミュノロジー	低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
US10179125B2 (en)	2014-12-01	2019-01-15	Zenith Epigenetics Ltd.	Substituted pyridines as bromodomain inhibitors
HK1245246A1 (zh)	2014-12-01	2018-08-24	恒翼生物医药科技(上海)有限公司	作为溴域抑制剂的取代吡啶酮
CA2969856A1 (en) *	2014-12-05	2016-06-09	Subramaniam Ananthan	Novel quinazolines as biogenic amine transport modulators
WO2016092375A1 (en)	2014-12-11	2016-06-16	Zenith Epigenetics Corp.	Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh)	2014-12-17	2021-05-14	恒翼生物医药科技(上海)有限公司	溴结构域的抑制剂
EP3247705B1 (en) *	2015-01-20	2019-11-20	Millennium Pharmaceuticals, Inc.	Quinazoline and quinoline compounds and uses thereof as nampt inhibitors
US11221329B2 (en) *	2015-10-30	2022-01-11	Lieber Institute, Inc.	Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
KR102327053B1 (ko) *	2017-03-16	2021-11-17	기초과학연구원	퀴나졸린, 퀴놀린 유도체 및 egfr 키나제 억제제로서의 용도
US11066420B2 (en)	2017-05-01	2021-07-20	Sanford Burnham Prebys Medical Discovery Institute	Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
EP3661919A4 (en) *	2017-08-02	2021-03-31	Northwestern University	SUBSTITUTED FUSION PYRIMIDINE COMPOUNDS AND THEIR USES
JP7315564B2 (ja) *	2018-02-02	2023-07-26	アジレント・テクノロジーズ・インク	グリカン分析のためのブロックされた２－ａａを使用するための方法およびキット
CA3102326A1 (en)	2018-07-26	2020-01-30	Domain Therapeutics	Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
SG11202105685TA (en) *	2019-01-03	2021-06-29	Univ Pittsburgh Commonwealth Sys Higher Education	Methods and materials for increasing transcription factor eb polypeptide levels
JP7478251B2 (ja) *	2019-12-14	2024-05-02	シャンハイイーストホスピタル（イーストホスピタル，トンジユニバーシティスクールオブメディシン）	イオンチャネルアンタゴニスト／遮断剤およびその用途
WO2021212010A2 (en)	2020-04-17	2021-10-21	The Trustees Of Indiana University	Small molecule antiviral drug treatment for human papillomavirus infections
WO2024258849A2 (en)	2023-06-13	2024-12-19	The Trustees Of Indiana University	Small molecule antiviral drug treatment for human papillomavirus infections

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE119051C (es)
NL292083A (es) *	1962-09-18
US3340260A (en) *	1962-12-03	1967-09-05	Ciba Geigy Corp	4-amino-pyrimidines
GB1199768A (en) *	1966-10-31	1970-07-22	Pfizer & Co C	Nitrogen Heterocycles and process for their preparation
US3637693A (en) *	1968-07-12	1972-01-25	Du Pont	Hydroxyarylquinazolines and their use as uv-absorbers
US3705898A (en) *	1970-01-26	1972-12-12	Morton Norwich Products Inc	Certain 4 - amino - 2-(5-nitro-2-thienyl) quinazolines and the intermediate 4 - chloro-(5 - nitro-2-thienyl)quinazolines therefor
DE2121031A1 (en) *	1971-04-29	1972-11-02	Dr. Karl Thomae Gmbh, 7950 Biberach	Base-substd quinazolines - thrombocyte aggregation inhibitors
US3819628A (en) *	1972-07-31	1974-06-25	Sandoz Ag	2-phenyl-4-substituted amino-quinazolines and nitrates thereof
CH612432A5 (es) *	1975-05-12	1979-07-31	Sandoz Ag
US4377582A (en) *	1979-12-19	1983-03-22	A. H. Robins Company, Inc.	2-Phenyl-4-[cis-2,5-dimethyl-4-(2-pyridinyl)-1-piperazinyl]quinazoline
US4306065A (en) *	1979-12-19	1981-12-15	A. H. Robins Company, Incorporated	2-Aryl-4-substituted quinazolines
JPS56120768A (en) *	1980-01-31	1981-09-22	Ciba Geigy Ag	Color developing quinazoline compound
JPS58172379A (ja)	1982-04-02	1983-10-11	Showa Denko Kk	新規なキナゾリン誘導体
KR100297623B1 (ko)	1993-06-17	2001-11-14	오츠까 요시미쯔	포스폰산디에스테르유도체
EP0655465B1 (de) *	1993-11-25	1997-07-30	BASF Aktiengesellschaft	Verfahren zum Beseitigen restflüchtiger Anteile aus Polyacrylatschmelzen
JPH083144A (ja)	1994-06-21	1996-01-09	Chugai Pharmaceut Co Ltd	キナゾリン及びキノリン誘導体
GB2295387A (en)	1994-11-23	1996-05-29	Glaxo Inc	Quinazoline antagonists of alpha 1c adrenergic receptors
FR2751656B1 (fr) *	1996-07-24	1998-10-16	Hoechst Marion Roussel Inc	Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
GB9718972D0 (en) *	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
AU719392B2 (en) *	1996-10-01	2000-05-11	Kyowa Hakko Kirin Co., Ltd.	Nitrogen-containing heterocyclic compounds
KR20000069431A (ko)	1996-12-13	2000-11-25	피터 지. 스트링거	Ｐｓａ의 효소 활성 억제제
JP3989102B2 (ja) *	1997-10-02	2007-10-10	エーザイ・アール・アンド・ディー・マネジメント株式会社	縮合ピリジン誘導体
DE19747063A1 (de) *	1997-10-24	1999-04-29	Basf Ag	3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
DE19756388A1 (de) *	1997-12-18	1999-06-24	Hoechst Marion Roussel De Gmbh	Substituierte 2-Aryl-4-amino-chinazoline
US6184226B1 (en) *	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
JP3018185B1 (ja) *	1999-02-12	2000-03-13	工業技術院長	キナゾリン誘導体又はその塩の製造方法
JP2001068452A (ja) *	1999-08-26	2001-03-16	Matsushita Electric Ind Co Ltd	回路パターン形成済シリコン基板のエッチング装置およびエッチング方法
JP2001089452A (ja)	1999-09-22	2001-04-03	Sankyo Co Ltd	ピリミジン誘導体
ES2156574B1 (es) *	1999-11-18	2002-02-01	Vita Invest Sa	Nuevos derivados de tiazolidindiona como agentes antidiabeticos
US6608053B2 (en) *	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
AU5261001A (en)	2000-04-27	2001-11-12	Imperial Cancer Research Technology Ltd	Condensed heteroaryl derivatives
AU2001277754B2 (en)	2000-08-10	2005-09-29	Mitsubishi Tanabe Pharma Corporation	Proline derivatives and use thereof as drugs
PL359920A1 (en)	2000-09-20	2004-09-06	Merck Patent Gmbh	4-amino-quinazolines
AU2003229305A1 (en)	2002-05-17	2003-12-02	Scios, Inc.	TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
AU2003255482A1 (en)	2002-10-02	2004-04-23	Merck Patent Gmbh	Use of 4 amino-quinazolines as anti cancer agents
DE602004014347D1 (de) *	2003-03-12	2008-07-24	Millennium Pharm Inc	Chinazolin-derivate als tgf-beta-inhibitoren
TWI289217B (en) *	2004-07-16	2007-11-01	Hon Hai Prec Ind Co Ltd	Light guide plate
US8283354B2 (en) *	2004-09-02	2012-10-09	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
US7928107B2 (en) *	2004-09-02	2011-04-19	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
US7718658B2 (en) *	2004-09-02	2010-05-18	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
RU2007127315A (ru) *	2004-12-17	2009-01-27	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Способы получения 4-аминохиназолинов
KR20080073749A (ko)	2005-11-14	2008-08-11	버텍스 파마슈티칼스 인코포레이티드	전압 개폐 이온 채널 조절제로서 유용한 퀴나졸린

2004
- 2004-03-02 CL CL200400409A patent/CL2004000409A1/es unknown
- 2004-03-03 EP EP04716887A patent/EP1608632B1/en not_active Expired - Lifetime
- 2004-03-03 TW TW093105557A patent/TW200426147A/zh unknown
- 2004-03-03 AT AT04716887T patent/ATE453629T1/de active
- 2004-03-03 UY UY28215A patent/UY28215A1/es not_active Application Discontinuation
- 2004-03-03 JP JP2006509028A patent/JP5247027B2/ja not_active Expired - Fee Related
- 2004-03-03 KR KR1020057016287A patent/KR20050108379A/ko not_active Ceased
- 2004-03-03 AU AU2004217891A patent/AU2004217891B2/en not_active Ceased
- 2004-03-03 WO PCT/US2004/006451 patent/WO2004078733A1/en not_active Ceased
- 2004-03-03 DE DE602004024873T patent/DE602004024873D1/de not_active Expired - Lifetime
- 2004-03-03 AR ARP040100670A patent/AR044502A1/es not_active Application Discontinuation
- 2004-03-03 CA CA002517844A patent/CA2517844A1/en not_active Abandoned
- 2004-03-03 BR BR0408026-2A patent/BRPI0408026A/pt not_active IP Right Cessation
- 2004-03-03 ES ES04716887T patent/ES2338553T3/es not_active Expired - Lifetime
- 2004-03-03 US US10/792,688 patent/US7678802B2/en not_active Expired - Lifetime
- 2004-03-03 RU RU2005130486/04A patent/RU2378260C2/ru not_active IP Right Cessation
- 2004-03-03 PE PE2004000236A patent/PE20041059A1/es not_active Application Discontinuation
- 2004-03-03 NZ NZ542664A patent/NZ542664A/en unknown
2005
- 2005-09-04 IL IL170636A patent/IL170636A/en not_active IP Right Cessation
- 2005-10-03 NO NO20054546A patent/NO20054546L/no not_active Application Discontinuation
2010
- 2010-01-15 US US12/688,163 patent/US8343980B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PE20041059A1 (es)	2005-02-07
IL170636A (en)	2012-08-30
ATE453629T1 (de)	2010-01-15
RU2005130486A (ru)	2006-05-10
DE602004024873D1 (de)	2010-02-11
TW200426147A (en)	2004-12-01
AU2004217891A1 (en)	2004-09-16
US20040248890A1 (en)	2004-12-09
JP5247027B2 (ja)	2013-07-24
UY28215A1 (es)	2004-09-30
JP2006522119A (ja)	2006-09-28
US20110021495A1 (en)	2011-01-27
KR20050108379A (ko)	2005-11-16
AU2004217891B2 (en)	2011-06-23
NO20054546L (no)	2005-11-25
WO2004078733A1 (en)	2004-09-16
ES2338553T3 (es)	2010-05-10
US7678802B2 (en)	2010-03-16
NO20054546D0 (no)	2005-10-03
US8343980B2 (en)	2013-01-01
HK1088314A1 (en)	2006-11-03
CA2517844A1 (en)	2004-09-16
NZ542664A (en)	2009-03-31
BRPI0408026A (pt)	2006-02-07
EP1608632B1 (en)	2009-12-30
AR044502A1 (es)	2005-09-14
RU2378260C2 (ru)	2010-01-10
EP1608632A1 (en)	2005-12-28

Publication	Publication Date	Title
EA200601253A1 (ru)	2006-12-29	Преимущественно линейная шипучая лекарственная форма фентанила для перорального применения и способы введения
BR0313555A (pt)	2005-07-12	Aplicação de inibidores de ikb-cinase na terapia da dor
EE05509B1 (et)	2012-02-15	Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid
SE0301700D0 (sv)	2003-06-10	Novel compounds
EA200401471A1 (ru)	2005-06-30	Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
SE0101387D0 (sv)	2001-04-20	Novel compounds
EE200300403A (et)	2003-12-15	N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
ATE449079T1 (de)	2009-12-15	Pharmazeutische zusammensetzungen beinhaltend kristallsalze von 7-ä4-(4-fluorophenyl)-6- isopropyl-2-
DOP2011000074A (es)	2012-08-31	Compuestos y composiciones como inhibidores de proteina cinasa
CL2004000250A1 (es)	2005-01-07	Compuestos derivados de piperidina bencenosulfonamida o benzamida; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la psicosis, dolor, disfuncion de memoria y aprendizaje, esquizofrenia, demencia, defi
CY1112738T1 (el)	2016-02-10	Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
ATE409485T1 (de)	2008-10-15	Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
ATE350377T1 (de)	2007-01-15	Substituierte 3-pyrrolidin-indol-derivate
ATE354362T1 (de)	2007-03-15	Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
DE60315479D1 (de)	2007-09-20	Pyrimidinamid derivate und deren verwendung
CL2003001415A1 (es)	2005-01-07	Compuestos d derivados de naftil, quinolinil e isoquinolinil urea; composicion farmaceutica; y uso en el tratamiento y prevencion de condiciones de dolor y en el sibndrome del colon irritable y condiciones asociadas.
ATE260650T1 (de)	2004-03-15	Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
MEP20908A (en)	2010-06-10	Thienopyrazoles
CL2003002293A1 (es)	2005-01-14	Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular.
IL304563A (en)	2023-09-01	The compound n-(benzoyl)-phenylalanine, a pharmaceutical composition containing it, and its use
IL174249A0 (en)	2006-08-01	Heterocyclic compounds and pharmaceutical compositions containing the same
CL2004001365A1 (es)	2005-05-06	Compuestos derivados de 3-fluoropiperidina; composicion farmaceutica que lo comprende; y uso del compuesto para tratar o prevenir el dolor o la enfermedad de parkinson.
EE200100520A (et)	2002-12-16	N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
CL2004001421A1 (es)	2005-05-27	Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
DE60134735D1 (de)	2008-08-21	Neue neurokinin-antagonisten zum gebrauch als arzneimittel